StemCells, Inc. to Present at UBS Global Life Sciences Conference.PALO ALTO, Calif. -- StemCells, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :STEM) today announced that Martin McGlynn, President and Chief Executive Officer, will present at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY on Wednesday, September 26, 2007 at 10:00 a.m. Eastern Time. Mr. McGlynn plans to report on the progress of the Company's ongoing Phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. in neuronal ceroid lipofuscinosis Neuronal Ceroid Lipofuscinoses (NCL, also known as Batten Disease) is the general name for a family of at least eight genetically separate neurodegenerative disorders that result from excessive accumlation of lipopigments (lipofuscin) in the body's tissues. , plans for expanding the company's Neural Program to additional indications, and an update on the company's Liver Program, including a new initiative to develop a cell-based therapy for liver diseases. There will be a breakout session following the presentation at which Mr. McGlynn will be available to answer questions about the company. A live webcast of the presentation, including the slides used in the presentation, will be hosted on the company's web site at www.stemcellsinc.com. The audio portion of the presentation will also be available through the UBS Investment Bank web site at www.ibb.ubs.com. Replay of the presentation from either site will be accessible until October 27, 2007. About StemCells, Inc. StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system, liver and pancreas. The Company's programs seek to repair or repopulate neural, liver or other tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of HuCNS-SC[TM] cells, its highly purified, expandable population of human neural stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young . StemCells is currently conducting a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of its proprietary HuCNS-SC[TM] product as a treatment for neuronal ceroid lipofuscinosis (NCL NCL Norwegian Cruise Line NCL New Caledonia (ISO Country code) NCL National Consumers League (Washington, DC) NCL Neuronal Ceroid Lipofuscinosis (adult type) ). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative disease that affects infants and young children. Further information about the Company is available on its web site at: www.stemcellsinc.com. Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. ("the Company"). The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. Please refer to Item 1A of the Company's Annual Report on Form 10-K for risks and other factors that may affect the Company's business operations. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion